<SEC-DOCUMENT>0000950170-25-049297.txt : 20250402
<SEC-HEADER>0000950170-25-049297.hdr.sgml : 20250402
<ACCEPTANCE-DATETIME>20250402160523
ACCESSION NUMBER:		0000950170-25-049297
CONFORMED SUBMISSION TYPE:	4/A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250130
FILED AS OF DATE:		20250402
DATE AS OF CHANGE:		20250402

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Evans John M.
		CENTRAL INDEX KEY:			0001786304
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39208
		FILM NUMBER:		25804323

	MAIL ADDRESS:	
		STREET 1:		C/O BEAM THERAPEUTICS INC.
		STREET 2:		26 LANDSDOWNE STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Beam Therapeutics Inc.
		CENTRAL INDEX KEY:			0001745999
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		26 LANDSDOWNE STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		857-327-8775

	MAIL ADDRESS:	
		STREET 1:		26 LANDSDOWNE STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>4/A
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4/A
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4/A</documentType>

    <periodOfReport>2025-01-30</periodOfReport>

    <dateOfOriginalSubmission>2025-02-03</dateOfOriginalSubmission>

    <issuer>
        <issuerCik>0001745999</issuerCik>
        <issuerName>Beam Therapeutics Inc.</issuerName>
        <issuerTradingSymbol>BEAM</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001786304</rptOwnerCik>
            <rptOwnerName>Evans John M.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O BEAM THERAPEUTICS INC.,</rptOwnerStreet1>
            <rptOwnerStreet2>238 MAIN STREET</rptOwnerStreet2>
            <rptOwnerCity>CAMBRIDGE</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02142</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>CEO</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>true</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
                <footnoteId id="F1"/>
                <footnoteId id="F2"/>
            </securityTitle>
            <transactionDate>
                <value>2025-01-30</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>M</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
                <footnoteId id="F3"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>30000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.67</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>968659</value>
                    <footnoteId id="F4"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
                <footnoteId id="F1"/>
                <footnoteId id="F2"/>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.67</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-01-30</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>M</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
                <footnoteId id="F3"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>30000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F4"/>
            </exerciseDate>
            <expirationDate>
                <value>2028-05-08</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>30000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>69336</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">On February 3, 2025, the Reporting Person filed a Form 4 (the &quot;Original Form 4&quot;) that, among other things, reported the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan. The Original Form 4 inadvertently failed to disclose the exercise of derivative securities that occurred pursuant to the same Rule 10b5-1 trading plan, which occurred immediately prior to such sale. Accordingly, this Form 4/A is being filed to disclose the omitted transaction. Immediately following the transaction reported herein, the Reporting Person directly beneficially owned 968,659 shares of common stock of Beam Therapeutics Inc.</footnote>
        <footnote id="F2">(Continued from footnote 1) (&quot;BEAM&quot;), and accordingly, all disclosures of the amount of securities directly beneficially owned by the Reporting Person subsequent to the transaction reported herein and prior to the filing of this Form 4/A, including with respect to the transactions reported in the Original Form 4, should be deemed to be adjusted accordingly. As of the date the filing of this Form 4/A, the Reporting Person directly beneficially owns 938,659 shares of common stock of BEAM.</footnote>
        <footnote id="F3">These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024.</footnote>
        <footnote id="F4">On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,336 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the &quot;Price Condition&quot;). The portion of the award subject to the Price Condition vested in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>By: /s/ Christine Bellon, Attorney-in-fact</signatureName>
        <signatureDate>2025-04-02</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
